Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 6Withdrawn 4Terminated 3Recruiting 3Active not recruiting 2Unknown 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 18Neoplasm Metastasis 10Triple Negative Breast Neoplasms 9Lung Neoplasms 9Ovarian Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Endometrial Neoplasms 6Fallopian Tube Neoplasms 5Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Neoplasms 3Cholangiocarcinoma 3Adenocarcinoma 3Stomach Neoplasms 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Biliary Tract Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Vulvar Neoplasms 1Vomiting 1Uterine Neoplasms 1Small Cell Lung Carcinoma 1Sinonasal Squamous Cell Carcinoma 1Recurrence 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Pancreatic Adenocarcinoma Metastatic 1Pancreatic Adenocarcinoma 1

Interventions

pembrolizumab 38Blood Specimen Collection 38Bevacizumab 22Surveys and Questionnaires 18Standard of Care 18Radiotherapy 17Exercise 17Carboplatin 17Nivolumab 15atezolizumab 14Paclitaxel 14Cisplatin 14Drug Therapy 13Fluorouracil 12Cyclophosphamide 12Cetuximab 11Trastuzumab 10Pemetrexed 10Leucovorin 10Docetaxel 10Dexamethasone 10Oxaliplatin 9Biopsy 9pertuzumab 8olaparib 8Temozolomide 8Panitumumab 8Observation 8Irinotecan 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Neoplasms × Taxes × Clear all
NCT05256225 2026-05-27

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

National Cancer Institute (NCI)

Phase 3 Recruiting
360 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

NCT06385925 2026-04-24

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Tyligand Pharmaceuticals (Suzhou) Limited

Phase 1/2 Recruiting
440 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05382559 2026-04-14

A Study of ASP3082 in Adults With Advanced Solid Tumors

Astellas Pharma Inc

Phase 1 Recruiting
681 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡